Walleye Trading’s Titan Pharmaceuticals TTNP Stock Holding History

Walleye Trading’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4	Closed	-$89K	–	5197
2016 Q3	$89K	Buy	+4	New	+$77.7K	﹤0.01%	3383

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Trading's TTNP Position: Q4 2016 in Review

Walleye Trading sold out of Titan Pharmaceuticals (TTNP) in Q4 2016, closing a stake of 4 shares — an estimated $89K sold.

Walleye Trading first reported a position in TTNP in Q3 2016 and held it in 1 quarter. The position peaked at $89K in Q3 2016. 47 funds tracked by Wall St. Rank hold TTNP as of Q4 2016.

Walleye Trading reported no remaining Titan Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Walleye Trading sold 4 Titan Pharmaceuticals shares in Q4 2016, an estimated $89K.
Walleye Trading first reported a position in Titan Pharmaceuticals in Q3 2016 and held it in 1 quarter.
Walleye Trading's Titan Pharmaceuticals position peaked at $89K in Q3 2016.
47 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2016.

Based on Walleye Trading's 13F filing for Q4 2016, filed 14 Feb 2017.